Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Venet M, Lepine A, Maarouf A, Biotti D, Boutiere C, Casez O, Cohen M, Durozard P, Demortière S, Giorgi L, Maillart E, Mathey G, Mazzola L, Rico A, Camdessanche JP, Deiva K, Pelletier J, Audoin B.
Venet M, et al. Among authors: audoin b.
Mult Scler. 2024 Feb;30(2):261-265. doi: 10.1177/13524585231223069. Epub 2024 Jan 2.
Mult Scler. 2024.
PMID: 38166437